BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred StockBy Nasdaq OMXDec 7, 2017, 9:05 PM UTC
BusinessPeregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017By Nasdaq OMXDec 4, 2017, 9:05 PM UTC
BusinessAvid Bioservices Announces Appointment of Tracy Kinjerski as Vice President of Business OperationsBy Nasdaq OMXNov 29, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement AgreementBy Nasdaq OMXNov 28, 2017, 1:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 24, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid BioservicesBy Nasdaq OMXOct 19, 2017, 12:05 PM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent DevelopmentsBy Nasdaq OMXSep 11, 2017, 8:05 PM UTC
BusinessPeregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid BioservicesBy Nasdaq OMXSep 11, 2017, 12:05 PM UTC
